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Introduction
TheWorld Health Organization (WHO)
has recently announced its plan to eliminate
Human African trypanosomiasis (HAT).
The plan’s main focus is on the Trypano-
soma brucei gambiense subspecies, which
causes 97% of cases [1]. However, total
elimination from certain areas has proved
extremely difficult previously; there has
been ongoing parasite detection in several
foci in West Africa, despite effective screen-
ing programmes. This has focussed interest
on the potential role of asymptomatic
human carriers in contributing to transmis-
sion. In this report, we present a unique case
of a patient harbouring the parasite for
more than three decades before developing
stage 2 sleeping sickness [2].
Presentation of Case
A 62-year-old male (see Fig. 1 for sum-
mary timeline) was admitted to Bridgend
hospital in Wales in March 2012. He pre-
sented with a 3-month history of worsening
mobility, shuffling gait, fatigue, somno-
lence, emotional lability, and personality
change. Born in Eastern Sierra Leone, he
had moved to the United Kingdom in
1971, making two visits back to his home
country, the last of which was for 3 months
in 1983, with no subsequent travel to
Africa.
In 2000, during investigation of venous
leg ulcers, he was found to have a
normocytic anaemia (Hb 10.4 g/dl, (13.0–
17.0)), and erythrocyte sedimentation rate
(ESR) of 78 mm/hour, (1–20). Elevated
titres of anti-nuclear antibodies (1:100), anti-
nuclear cytoplasmic antibodies (1:160), and
Anti-Ro antibodies were detected. There
were no sicca symptoms and no specific
treatment for autoimmune disease was
instituted. He was kept under annual review;
the only medication given was tiabendazole
in 2005 for a persistent eosinophilia and
positive Strongyloides serology.
In 2007 a pituitary adenoma (with a
normal hormone profile) was detected on
magnetic resonance imaging (MRI) of the
brain during investigation of a unilateral
lower motor neurone seventh nerve palsy.
In 2008 a diagnosis of ‘‘atypical Sjo¨gren’s
syndrome’’ was made in light of persistent
autoantibodies. At this stage his haemo-
globin was 9.4 g/dl, platelets 1256109/L
(150–400), ESR 127 mm/hr, Immuno-
globulin M (IgM) levels were 20.6 g/L
(0.4–2.3), and Immunoglobulin G (IgG)
levels 32.6 g/L (7.0–16.0). In 2009 he was
started on prednisolone 10 mg daily fol-
lowing an episode of epiglottitis. Azathio-
prine was added and increased to a dose of
100 mg daily.
In 2010 the patient developed unilateral
thigh swelling and a transient rash. Borrelia
burgdorferi serology (IgM & IgG) was
positive and he received 2 weeks of
doxycycline. Elevated anticardiolipin anti-
bodies were detected and he was prescribed
aspirin (subsequently discontinued due to
epistaxis). A bone marrow examination was
advised to investigate persistent anaemia
and thrombocytopenia, but the patient
declined.
In 2011 osteoporosis was discovered
on a Dual-energy X-ray absorptiometry
(DEXA) scan; low testosterone levels
and high prolactin levels (70,400 U/L)
prompted treatment with testosterone gel
and cabergoline. MRI of the brain showed
no change in the pituitary adenoma. The
‘‘Sjo¨gren’s’’ diagnosis was reconsidered,
azathioprine was discontinued and pred-
nisolone reduced to 2.5 mg daily. Until
this point in the history, the patient had
remained relatively well, with no symp-
toms beyond those mentioned above.
Indeed, his wife stated ‘‘he had never
missed a day of work in his life.’’
In January 2012, the patient developed
unsteadiness and had three falls at home.
He was admitted to hospital in March
2012 with rapidly deteriorating mobility,
alteration in his sleep–wake cycle, and
episodes of drowsiness. Neurological ex-
amination demonstrated rigidity, bradyki-
nesia, and a right lateral gaze palsy. An
initial diagnosis of Parkinsonism resulted
in treatment with carbidopa/levodopa
with minimal benefit. A few days into his
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admission, he developed fevers and longer
sustained episodes of unresponsiveness. He
was treated for possible meningoencepali-
tis with aciclovir and ceftriaxone. Hydro-
cortisone (400 mg daily) was commenced
to cover pituitary apoplexy which was
subsequently excluded on imaging. A
cerebrospinal fluid examination revealed
250 lymphocytes/mm3, protein 0.57 g/L,
and a normal glucose ratio; gram stain,
bacterial culture, and PCR for herpes
viruses were negative.
An MRI of the brainrevealed nonspe-
cific white matter changes around the
basal ganglia and multiple radiolucent
lesions in the skull vault. Serum and urine
electrophoresis did not detect a parapro-
tein, and a skeletal survey was normal.
HIV and treponemal serologies were
negative. Since the patient continued to
experience symptoms of drowsiness, a
diagnosis of encephalitis lethargica was
entertained. Further results demonstrated
high levels of voltage gated potassium
channel–complex (VGKC-complex), anti-
bodies, and moderate levels of N-methyl-
D-aspartate (NMDA) receptor antibodies.
He developed further episodes of unre-
sponsiveness, and a generalised tonic-
clonic seizure followed by persistent coma
prompted transfer to a neurology ward
with a view to intravenous immunoglob-
ulin for a presumed autoimmune enceph-
alitis. Meanwhile, microscopy of a bone
marrow trephine demonstrated multiple
Trypanosoma brucei trypomastigotes, sub-
sequently seen in the peripheral blood. He
was intubated, and on 5 May, urgent
airborne transfer to the critical care unit at
the Hospital for Tropical Diseases in
London was arranged.
Treatment was commenced immediate-
ly with NECT (nifurtimox-eflornithine
combination therapy), with oral nifurtimox
5 mg/kg every 8 hours and intravenous
eflornithine 200 mg/kg every 12 hours,
which is the recommended first-line thera-
py for stage 2 HAT [1]. NECT was chosen
over the eflornithine monotherapy (the
alternative treatment for stage 2 HAT),
since it has shown to be equally efficacious
whilst causing less severe haemotological
side effects. Furthermore, treatment with
NECT is of shorter duration and requires
fewer infusions, minimizing the chance of
line related complications [1].
On Day 4 of the Intensive Therapy
Unit (ITU) admission, the patient was
promptly extubated and transferred to the
ward shortly afterwards, with complete
reversal of coma and resolution of pancy-
topenia. Cerebrospinal fluid (CSF) exam-
ination revealed a positive indirect fluo-
rescent antibody test (IFAT) for T. b.
gambiense, with a titre of 1/32, and serum
IFAT was positive at 1/3200. Analysis of a
stored serum sample from 2004 demon-
strated a T. b. gambiense IFAT titre of 1/
800.
On Day 9 of NECT treatment the
patient started to become drowsy once
again, requiring reintubation. A computed
tomography (CT) scan of the brain
showed no acute changes. Repeat CSF
and blood exams showed no evidence of
trypanosomes. Nonconvulsive status was
excluded by electroencephalogram. Be-
cause of the laboratory evidence of
effective treatment and the overlap in
clinical features of autoimmune encepha-
litis with persistently high VGKC-complex
antibodies, plasma exchange (PEX) was
commenced. After four cycles of PEX, the
patient showed clinical improvement and
was extubated. Unfortunately, following
further neurological deterioration, the
patient was reintubated and a surgical
tracheostomy inserted. Repeat lumbar
puncture showed improvement of CSF
markers (protein 0.43 g/L, white cells 8/
mm3) with no trypanosomes observed in
CSF or blood. All subsequent films were
negative. Sleep–wake cycle disturbance
continued for the next few weeks with
occasional apnoeic episodes, and resulted
in a decision to administer a further five
cycles of PEX, which was followed by
sustained recovery (associated with a decline
in VGKC-complex antibodies below the
‘‘positive’’ threshold of 100pM) and dis-
charge home in August 2012. At outpatient
review 1 month later, all extrapyramidal
features had resolved, with considerable
improvement in mobility and cognition.
Repeat CSF examinations in February
(CSF: Protein 0.27, 8 lymphocytes, CSF
T. b. gambiense IFAT 1:8) and October
2013 (CSF: protein 0.27, 0 lymphocytes,
CSF T.b.gambiense IFAT 1:8) reflected the
ongoing clinical recovery.
Case Discussion
Trypanotolerance
To date, this case represents the longest
duration of HAT infection ever reported.
As our patient last visited an endemic
country in 1983 and became unwell in
2012, the period from infection to stage 2
symptoms must have been at least 29
years.
This case provides concrete evidence
behind the emerging concept of ‘‘human
trypanotolerance,’’ which challenges the
Fig. 1. Timeline of the patient’s clinical course. Timeline is not to scale. Abbreviations: Ab: Antibody ANA: anti-nuclear antibody, ANCA: anti-
neutrophil cytoplasmic antibody, BM Bx: bone marrow biopsy, CSF: cerebrospinal fluid, ED: Emergency department, ENA: extractable nuclear
antigens, ESR: erythrocyte sedimentation rate, Hb: haemoglobin, LP: lumbar puncture, MRI: magnetic resonance imaging, NECT: nifurtimox-
eflornithine combination therapy, NMDA: N-methyl-D-aspartate receptor, PEX: Plasma exchange, PCR: polymerase chain reaction, Plts: platelets, Rx:
treated with, VGKC: complex voltage gated potassium channel-complex, WCC: white cell count.
doi:10.1371/journal.pntd.0003349.g001
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traditionally held view that, left untreated,
HAT always progresses to the fatal stage
2 phase. Checchi, et al., reviewed the
prior trypanotolerance literature, which
consists of cases showing an extended
duration of infection, like the one dis-
cussed above, as well as cohorts demon-
strating spontaneous resolution of infec-
tion [3]. We have summarised and
updated the key evidence in this review,
illustrated geographically in Fig. 2 [4–12].
In our case, we were able to demonstrate
the presence of long standing HAT
infection, using several molecular tech-
niques that were not available in the past.
First, historically, it had not been possible
to confirm whether chronic infections
were due to pathogenic trypanosome
species, as diagnosis was based on mi-
croscopy, which does not allow differen-
tiation of sub-species [3]. However, PCR
amplification of our patient’s parasite
DNA clearly indicated T. b. gambiense
group 1 [13]. Second, retrospective test-
ing of a serum sample in 2004 demon-
strated clear evidence of serological infec-
tion prior to disease. Third, additional
microsatellite typing showed clustering
with field isolates taken from West Africa
in the 1980s (Fig. 3), which is the
estimated time our patient would have
been first infected. Our findings are
consistent with a recent 15-year follow-
up study of untreated stage 1 HAT
patients in the Ivory Coast, which showed
that whilst some patients progress to stage
2, a proportion of patients become
asymptomatic carriers, and another sub-
set appears to self cure [7].
Elucidating the genetic basis underlying
trypanotolerance is of great interest. Al-
though few parasite factors have been
discovered, associations between human
genes involved in the immune response
and susceptibility to HAT have been
reported [14,15].
Implications for public health and
disease control
Current disease control strategies rely
on case finding and treatment of patients
with detectable parasites in lymph nodes
or blood or laboratory evidence of stage 2
disease [16]. Such strategies could fail to
stop transmission if there exist hidden
populations of individuals that harbour
undetectably low parasite numbers and act
as reservoirs of infection [2,17]. Evidence
that seropositive, microscopy-negative pa-
tients have low-level infection is supported
by molecular diagnostic work demonstrat-
ing detectable circulating T. b. gambiense
DNA in a proportion of these asymptom-
atic carriers [7,18]. Their potential role in
disease transmission is supported by a
parasite population genetic study [19] as
well as by research in trypanotolerant cattle
[20]. Detecting asymptomatic carriers is
particularly challenging due to the lack of a
specific diagnostic test that can be used in
remote field settings. However, a recent
study using blood stored on filter paper
with the immune trypanolysis test has
shown promising results [21].
As the focus of HAT programs shifts
towards elimination of the disease, it is
essential that trypanotolerance is taken
into account [22]. Specifically, the follow-
ing questions will need to be answered:
How common are these asymptomatic
carriers? Does their prevalence vary in
different HAT foci? How can they best be
detected and monitored? What is the
attributable fraction of transmission asso-
ciated with failure to detect and treat such
cases?
Immunopathology
Several features of this case generate
hypotheses about the immunopathology of
HAT.
The factors that led to our patient’s
development of stage 2 disease after such
a long duration of chronic infection
are unknown, but it is feasible that
Fig. 2. Map showing reports of spontaneous clearance of infection (blue squares), or extended duration of infection (red squares).
Abbreviations: sc: spontaneous clearance of infection, y: years. References: [4–11]. Adapted from [3].
doi:10.1371/journal.pntd.0003349.g002
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immunosuppressive therapy (azathioprine
and prednisolone) may have played a role.
While immunosuppressive therapy is well
described when used for other protozoal
infections [23], this is the first such case
reported for HAT. This may be due to the
low prevalence of HAT in populations at
risk of iatrogenic immunosuppression. HIV
and HAT have considerable geographic
overlap; limited evidence does not suggest
an increased risk of HAT among HIV+
persons [24], but there is no data on the
role of HIV in activation of latent HAT
infections, a mechanism well established for
Chagas trypanosomiasis [25]. One can
speculate that the immunosuppressive ther-
apy somehow altered the tight balance
between immune control and disease.
The complex clinical course of our patient
before diagnosis of HAT warrants atten-
tion. For more than a decade, our patient
was diagnosed with a series of conditions
(Sjo¨gren’s, Lyme, antiphospholipid disease)
based on abnormal serological tests. We
consider these to be false-positive results,
due to nonspecific immune activation
characteristic of long-standing HAT infec-
tion. Through continuous antigenic varia-
tion of their variant surface glycoprotein,
trypanosomes evade the immune system,
inducing polyclonal B cell activation [26],
which produces hypergammaglobulinae-
mia and autoantibodies [27,28].
We hypothesise that the clinical course
of our patient after definitive treatment
may be similarly related to an autoim-
mune component. Most patients present-
ing with stage 2 HAT in field settings
respond to treatment with rapid improve-
ment within days. Whereas it is not
uncommon for patients given melarsoprol
to develop a post-treatment reactive
encephalopathy, such a syndrome has
been described as less frequent with
NECT [29]. Our patient had an unchar-
acteristically slow improvement following
NECT with a fluctuating sleep disorder
lasting several weeks. We believe that this
could be due to immune-mediated ence-
phalopathy. Indeed, our patient was
found to be positive for VGKC-complex
antibodies, which are known to cause
autoimmune encephalitis [30]. This led us
to administer plasma exchange, with clin-
ical improvement mirroring the fall in
antibody titres. One might postulate that
VGKC-complex antibodies may therefore
contribute to stage 2 immunopathogenesis.
However, a stored serum sample from
5 years before onset of stage 2 symptoms
was also strongly positive (1628 pM; nor-
mal range,100 pM), so other insults must
be required to generate pathology, such as
the blood-brain barrier breakdown that
must have occurred during the trypanoso-
mal invasion. Improved understanding of
CNS immunopathology is important, as
it may help to design better and safer
treatments.
Fig. 3. Phylogenetic tree depicting the relationship between our patient’s parasite and field isolates taken between 1978–1983.
Neighbour joining tree of T. b. brucei, T. b. gambiense group 1 and T. b. gambiense group 2 isolates from Cote d’Ivoire and T. b. gambiense group 1
isolates from Cameroon and the Democratic Republic of Congo. Our patient’s isolate clustered most closely with other Type 1 isolates from Cote
d’Ivoire.
doi:10.1371/journal.pntd.0003349.g003
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Conclusion
Although we report only on a single
patient, this case adds to the accumulating
evidence of human trypanotolerance, thus
further stimulating debate about the
impact of this phenomenon in the field
and illuminating new avenues of research
that must be explored if we are to provide
the answers that are vital for the elimina-
tion of this neglected tropical disease.
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N It adds strong evidence behind human trypanotolerance, which has important
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HAT, which necessitate further research
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